PND14 MEDICATION COSTS OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN GERMANY  by Eidt, D et al.
1999–2004, ages 16–64 years, were selected from a privately
insured claims database with 6+ million beneﬁciaries. Control
group was an age and gender matched cohort of randomly
chosen beneﬁciaries without epilepsy. All were required to have
continuous health coverage during 2004 (baseline) and 2005
(study period). Chi-squared tests were used to compare baseline
comorbidities. Wilcoxon rank-sum tests were used for univariate
comparisons of annual direct (medical and pharmaceutical) costs
to insurers during the study period. RESULTS: Patients with
epilepsy averaged 43 years old, and there were more females
(57%). Compared with controls, epilepsy patients had signiﬁ-
cantly higher rates of mental health disorders, comorbidities
included in the Charlson Comorbidity Index (e.g., cerebrovascu-
lar disease, congestive heart failure, COPD, rheumatologic
disease, cancer), migraine, and other neurological disorders. On
average, direct annual costs were signiﬁcantly higher for epilepsy
patients ($10,258) compared with controls ($3,862), difference
of $6,396, P < 0.0001. Outpatient services accounted for 34%,
inpatient services for 28%, and drug costs for 27% of epilepsy
patients’ annual direct costs. Among epilepsy patients, non-
epilepsy costs accounted for $8201 (80%) on average and
epilepsy-related costs (i.e., costs for antiepileptic drugs, claims
with an epilepsy or convulsions diagnosis, neurology visits, and
selected diagnostic procedures) accounted for $2057 (20%).
Approximately 13% ($1047) of non-epilepsy costs were attrib-
utable to mental health-related expenditures. CONCLUSIONS:
Patients with epilepsy had signiﬁcantly higher costs compared
with matched controls. The excess costs of epilepsy patients are
underestimated when looking only at epilepsy-related costs.
Epilepsy-related costs represented 20% of the annual direct costs
of epilepsy patients and almost one-third of the difference in costs
between epilepsy patients and controls.
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OBJECTIVES: A national multicentre retrospective study
(EPIZOD) based on medical records review was conducted
among a sample of general practitioners, dermatologists, neu-
rologists and anti-pain centers. Main EPIZOD objectives were
to estimate annual incidence of Herpes Zoster (HZ) and the
proportion of patients developing Post-Herpetic Neuralgia
(PHN) in France. PHN was deﬁned as “persistence of pain at
least one month after rash onset”. An economic study was
carried out in a sample of patients included in EPIZOD to
estimate costs associated with HZ and PHN management in
patients aged more than 50 in France. METHODS: Costs of
health resources utilization, including consultations, examina-
tions, treatments (i.e. drugs and non-pharmacological treat-
ments), hospitalizations and sick leaves, were valued according
to ofﬁcial tariffs and weighted by patients’ treatment patterns.
Estimations were calculated according to both Third Party
Payer (TPP) and societal perspectives. RESULTS: Among 862
HZ and 412 PHN patients included in EPIZOD, 108 and 88
patients, respectively, were recruited for the economic study.
Mean cost per HZ case was estimated to be €182.92 for TPP
and €346.78 for the society. Each PHN case was assessed to
cost on average €339.84 and €555.56 respectively. Main costs
drivers for TPP were treatments (about 50% of total costs),
followed by hospitalizations and medical consultations (about
20% each). Based on EPIZOD incidence estimations, annual
cost associated with HZ and PHN management would reach
€61.0 million for TPP and €108.5 million for the society. CON-
CLUSIONS: This study suggests that HZ and PHN are costly
diseases in France. In this context, our ﬁndings will be useful for
policymakers when assessing HZ and PHN control measures,
including the introduction of a vaccine.
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OBJECTIVES: Alzheimer’s disease is a chronic, progressive
disease, characterized by deterioration of cognitive function. The
prevalence rate of Alzheimer’s disease is 10 percent in people
over the age of 70, and 40 percent for people over age 90. There
is no cure for Alzheimer’s disease therefore the goal of treatment
is to control the signs and symptoms of the disease through
prescription medications. At the national level, research is
lacking in the area of prescription medication costs for Alzhe-
imer’s disease. The objectives of this study were to estimate the
number and cost of prescription medications for Alzheimer’s
disease in the United States. METHODS: The Medical Expendi-
tures Panel Survey is a nationally representative sample of the
non-institutionalized, civilian population in the United States.
Data from the 2004–2005 Medical Expenditures Panel Survey
were used to estimate the cost of prescription medications for
Alzheimer’s disease. To test for a difference between costs of
prescription medications for gender, a t-test was used. A series of
one-way ANOVA analyses were used with each of the remaining
demographic variables (age, marital status, income and region of
residence) serving as the independent variable and the cost of
Alzheimer’s prescription medications as the dependent variable.
RESULTS: Over 1.9 million people reported having Alzheimer’s
disease in 2004 and 2005. Over the two year period, these
patients reported having over 10 million prescriptions ﬁlled for
Alzheimer’s medications at a cost of over $1.3 billion in U.S.
dollars. CONCLUSIONS: The most rapidly growing segment of
the population by the year 2030 will be people over the age of 85.
Because life expectancy is increasing and the risk of developing
Alzheimer’s increases with age, this cost of prescription medica-
tions estimation has both current and future relevance for health
care insurers, providers, administrators, policy makers and
Alzheimer’s patients.
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OBJECTIVES: CF patients need specialized long-term medica-
tion. In order to support lung function inhalable pharmaceuticals
like bronchodilators, mucolytica or anti-inﬂammatory drugs are
used. Oral or inhalable antibiotic therapy is especially important
for patients whose lung has a chronic colonization with germs. In
case of pancreatic insufﬁciency digestive enzymes have to be
substituted and patients need an additional supplement of vita-
mins as well as high caloric food. All of these aspects lead to high
medication in CF patients. Hence, aim of this work is to analyse
medication mixtures and related costs for CF in Germany.
METHODS: Medication data was evaluated in seven different
outpatient CF centres. Data was recorded via medication lists by
the physicians reporting name of medication, dosage and phar-
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maceutical form. As the medication is mostly a long-term
regimen these resource uses were valued using biggest available
packages. Prices were taken from the German “Rote Liste” with
2006 as price year. In addition, cost-inﬂuencing factors were
analysed via correlation analyses. RESULTS: A total of 3150
pharmaceutical records from 301 CF patients were collected.
Annual and daily medication costs were analysed for different
age groups. Mean annual costs for medication are €21,603 per
patient (range: €69; €86,790). Correlation analyses showed sig-
niﬁcant correlations (p = 0.01) between costs of medication and
age, co-morbidities (like pancreatic insufﬁciency and diabetes
mellitus and clinical parameters like the colonization of the lung
with germs) as well as functional parameters (% of vital capacity,
FEV1, MEF25). E.g. mean annual costs for medication are
€14,884 (€23,815) for patients without (with) colonization of
the lung with germs. Other correlation factors yielded similar
cost dispersions in (un)affected patients. CONCLUSIONS:
CF patients need specialized medication depending on age,
co-morbidities and other clinical parameters. Non-optimal
treatment leads to signiﬁcantly higher costs for the health care
system.
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OBJECTIVES: Compare annual indirect costs between privately
insured employees with epilepsy and matched employee con-
trols. METHODS: Employees with greater than or equal to 1
epilepsy diagnosis (ICD-9-CM: 345.x) in 2004, ages 18–64
years, were selected from a privately insured claims database
containing disability data from 17 U.S. companies. A random
sample of age and gender matched employees without epilepsy
was selected as a control group. All were required to have con-
tinuous health coverage during 2004 (baseline) and 2005 (study
period). Chi-squared tests were used to compare baseline comor-
bidities and differences in indirect resource use (disability and
medically-related absenteeism). Wilcoxon rank-sum tests were
used for univariate comparisons of mean disability and
medically-related absenteeism days and associated annual indi-
rect costs during the study period. Two-part models were used to
compare indirect costs adjusting for differences in demographic/
clinical characteristics. RESULTS: Employees with epilepsy
(n = 1,866) averaged 48.4 years old (SD  10.4), and 55% were
male. Compared with controls, employees with epilepsy had
signiﬁcantly higher rates of mental disorders, substance abuse,
other neurological disorders and physical disorders measured by
the Charlson Comorbidity Index. Employees with epilepsy were
more likely to have a short- or long-term disability claim com-
pared with controls (16.5% vs 5.6%, respectively; P < 0.0001),
resulting in higher mean number of annual disability days (38.6
vs 6.6, respectively, P < 0.0001) and higher annual disability
costs ($1836 vs $338, respectively; P < 0.0001). Medically-
related absenteeism costs were also higher for employees with
epilepsy compared with controls ($1356 vs $904, respectively;
P < 0.0001). Average total indirect costs for employees with epi-
lepsy were $3912 vs $1242 for controls (P < 0.0001) and
remained signiﬁcantly higher after adjusting for patient charac-
teristics ($2793 vs $1578, respectively; P < 0.0001). CONCLU-
SIONS: Employees with epilepsy were three times more likely to
have disability workloss, had six times the number of disability
days, and three times higher indirect costs compared with
matched employee controls.
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OBJECTIVES: The objectives of this study were to estimate the
number of people with Alzheimer’s related morbidity and mor-
tality and to estimate the indirect costs for Alzheimer’s disease
in the United States. Alzheimer’s disease is a chronic progres-
sive disease with a prevalence rate of 10% of the United States
population at age 70 and a prevalence rate of 40% by age 90.
METHODS: The Human Capital method was used to estimate
indirect costs for Alzheimer’s disease. The Medical Expendi-
tures Panel Survey, a nationally representative database of U.S.,
non-institutionalized civilians was used to estimate the morbid-
ity (missed work and bed days) portion of indirect costs. The
value of a bed day was estimated at 40% of the daily wage rate
the person would have earned if they were in the workforce.
The 2004 National Vital Statistics Survey Mortality Data was
used to estimate the mortality portion of indirect costs for
Alzheimer’s disease. RESULTS: A total of 26,745,385 bed days
were reported by patients with Alzheimer’s in 2004. Of the
65,965 deaths that were reported due to Alzheimer’s, 8,320
occurred prior to life expectancy. In U.S. dollars the overall
total for indirect costs for Alzheimer’s patients in 2004 was
over $1.3 billion. The majority of indirect costs for people with
Alzheimer’s were due to morbidity. CONCLUSIONS: By the
year 2030, population estimates predict the most rapidly
growing population segment will be those 85 and older. Given
the increasing prevalence of Alzheimer’s disease with advancing
age, the number of persons developing Alzheimer’s disease will
increase dramatically over the next several decades as will the
indirect costs. This study most likely underestimates the mor-
bidity costs of Alzheimer’s disease because patients in nursing
homes and other institutions are not included in the Medical
Expenditures Panel Survey.
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OBJECTIVES: Our recent study has found that pharmacologi-
cal management of epilepsy within outpatient setting of Mon-
tenegro has been slightly different in comparison to developed
countries. This was probably the consequence of many medical
and non-medical inﬂuences, whose separate contribution to
prescribing cannot be fully explained. In this study we investi-
gated the one-year expenses for the outpatient pharmacological
management of epilepsy in our country, with particular high-
light on potential cost-saving. METHODS: Data about antiepi-
leptics (ATC code N03) which were prescribed for the
treatment of epilepsy (G40 code according to ICD-X revision)
during 2005 were extracted from the National database which
was set up within Republic Health Insurance Fund of Mon-
tenegro since 2003. Standard DDD/ATC (deﬁned daily dose/
anatomic-therapeutic-chemical) methodology for the outpatient
drug utilization was used. Than we multiplied the number of
prescribed DDDs per 1000 inhabitants per day (DTIDs) with
the average price of one DDD for each drug. Our country has
a population of approximately 660,000 people and currency is
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